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Abstract. The signaling capacity of endogenous cannabinoids ("endocannabinoids") is tightly regulated by degradative enzymes. This Perspective highlights a research article in this issue (p. XXX), where the authors show that genetic disruption of monoacylglycerol lipase (MAGL), the principal degradative enzyme for the endocannabinoid 2-arachidonoylglycerol (2-AG), causes marked elevations in 2-AG levels that lead to desensitization of brain cannabinoid receptors. These findings highlight the central role that MAGL plays in endocannabinoid metabolism in vivo and reveal that excessive 2-AG signaling can lead to functional antagonism of the brain cannabinoid system.
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The endogenous cannabinoid (endocannabinoid) system modulates a wide range of physiological processes in mammals, including pain and inflammation, feeding and energy regulation, learning and memory, and emotionality (Fowler, 2006; Pacher et al., 2006) .
Components of this system include the cannabinoid receptors CB 1 and CB 2 , the endocannabinoids N-arachidonylethanolamine (anandamide; AEA) and 2-arachidonylglycerol (2-AG), and the enzymes responsible for endocannabinoid biosynthesis and degradation (Ahn et al., 2008; Di Marzo et al., 2007) . While direct agonists for cannabinoid receptors, such as Δ 9 -tetrahydrocannabinol (THC), the primary psychoactive constituent of Cannabis sativa, produce well-known medicinal effects such as analgesia, they also possess dependence liability and cause detrimental effects on fine motor control and cognition that limit their broad therapeutic potential. Amplifying the actions of endocannabinoids by inhibiting their enzymatic degradation has emerged as an alternative strategy to exploit the endocannabinoid system for possible clinical benefit. Still, much remains unknown about the pharmacological and behavioral impact of disrupting endocannabinoid metabolism. Termination of endocannabinoid signaling is carried out primarily by two hydrolytic enzymes in the nervous system, fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996) , which degrades AEA, and monoacylglycerol lipase (MAGL) (Blankman et al., 2007; Dinh et al., 2002) , which breaks down 2-AG. A considerable body of research has demonstrated that FAAH inhibitors reduce pain in a wide range of acute, inflammatory, neuropathic pain models (Chang et al., 2006; Lichtman et al., 2004; Russo et al., 2007) . More recently, a MAGL inhibitor has been demonstrated to reduce acute and neuropathic pain Long et al., 2009 ).
In this issue of Molecular Pharmacology, Chanda et al. (Chanda et al., 2010) reveal that targeted disruption of the MAGL (or MGLL) gene leads to severe disturbances in the ability of mice to metabolize the endogenous cannabinoid 2-arachidonylglycerol (2-AG), resulting in
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This article has not been copyedited and formatted. The final version may differ from this version. (Schlosburg et al., 2010) . These effects were phenocopied by chronic treatment with the selective MAGL inhibitor JZL184, which also caused tolerance to the antiallodynic effects of acute MAGL inhibition, cross-tolerance to the antiallodynic effects of FAAH inhibition, and profound deficits in endocannabinoid-mediated short-term synaptic plasticity. In marked contrast to the consequences of chronic elevation of 2-AG, the analgesic effects of a FAAH inhibitor persisted after chronic administration, despite the fact that equi-effective analgesic doses of JZL184 and the FAAH inhibitor were used. As has been observed previously in FAAH (-/-) mice (Cravatt et al., 2001b; Lichtman et al., 2002) , CB 1 receptor function remained normal following chronic pharmacological inhibition of FAAH (Schlosburg et al., 2010) 
This article has not been copyedited and formatted. The final version may differ from this version. Collectively, the studies by Chanda and colleagues and Schlosburg and coworkers point to a model where chronic disruption of MAGL leads to heightened 2-AG levels that cause tonic activation and eventual desensitization of the brain CB 1 system (Figure 1) . As an interesting contrast, CB 2 receptors in spleen remain unperturbed in MAGL (-/-) mice (Chanda et al., 2010) .
The underlying mechanisms for the differential down-regulation between CB 1 and CB 2 receptors in MAGL (-/-) mice remain an open question. However, one can speculate that a difference between brain and spleen 2-AG levels may be a driving force for the distinct adaptations in the two cannabinoid receptors. Spleen 2-AG levels are, for instance, 'only' elevated by two-threefold in MAGL(-/-) mice (in contrast to the > 10-fold elevations in brain 2-AG levels in these animals) (Chanda et al., 2010; Schlosburg et al., 2010) . Under this hypothesis, one might expect that, following chronic elevations of 2-AG, both CB 1 and CB 2 receptors would be downregulated in the CNS, while neither receptor would be altered in peripheral tissue. Alternatively, CB 1 receptors may be more likely to undergo internalization and down-regulation in response to 2-AG than CB 2 receptors. Based on these differential effects, one might expect that chronic administration of MAGL inhibitors would have minimal effects on CB 2 receptor mediated actions.
We have learned from the results of Chanda et al. (Chanda et al., 2010) and Schlosburg et al. (Schlosburg et al., 2010) not only that MAGL is the primary catabolic enzyme responsible for terminating 2-AG function in the nervous system, but also that maximal elevations in 2-AG signaling overload CB 1 receptor pathways leading to their downregulation and dampened responses to endogenous and exogenous cannabinoids. Do these results negate the possibility of using MAGL inhibitors for chronic pain conditions? Perhaps, but another consideration is that partial MAGL blockade will retain analgesic efficacy without resulting in CB 1 down-regulation.
Other interesting questions include: why does disrupting FAAH activity lead to robust analgesic effects that do not tolerize? Might this reflect different modes of CB 1 receptor activation by AEA and 2-AG? Finally, might certain neural circuits maintain an intact CB 1 receptor system even in
This article has not been copyedited and formatted. The final version may differ from this version. Following chronic MAGL blockade, elevated 2-AG levels cause tonic activation and eventual internalization and downregulation of CB 1 receptors.
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